# Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

Study · id `cardio:ct-nct03284463` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03284463](<https://clinicaltrials.gov/study/NCT03284463>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03284463

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

## Technical summary

Registry record NCT03284463. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-01 (actual); primary completion 2022-08-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 306 participants (enrolled count; ClinicalTrials.gov record NCT03284463, source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)
- Started: 2018-01-01 (actual) (ClinicalTrials.gov record NCT03284463, source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)
- Primary completion: 2022-08-28 (actual) (ClinicalTrials.gov record NCT03284463, source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)
- Completion: 2023-05-28 (actual) (ClinicalTrials.gov record NCT03284463, source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03284463, source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03284463-2023-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism
- Acronym: SE-GRACE
- Condition: Acute Stroke
- Intervention (Drug): Glibenclamide
- Intervention (Drug): Placebo
- Lead sponsor: Nanfang Hospital, Southern Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Nanfang Hospital, Southern Medical University (`cardio:org-nanfang-hospital-southern-medical-university`)

## Provenance

Content hash: 25e49a3b814301e9c297314b3c3b2dbc81949ee1aa1d8103319ea70b16d3da47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
